TransMedics Group, Inc. (TMDX) experienced a pre-market plunge of 21.52% on Wednesday. The sharp decline followed the release of the company's first-quarter fiscal year 2026 financial results, which revealed a significant earnings miss and deteriorating profitability.

The medical technology company reported adjusted earnings per share of $0.30, missing the analyst consensus estimate of approximately $0.61 by about 50% and representing a 59% decline from the $0.74 reported in the same quarter last year. While revenue of $173.9 million slightly exceeded expectations, net income plummeted 72% year-over-year to $7.3 million, and operating income fell 52% to $13.3 million. The company's gross margin also narrowed to 58% from 61% a year ago.

The earnings shortfall was primarily driven by higher operating expenses, including increased investments in research and development and organizational spending to support growth initiatives. Following the results, several analysts cut their price targets on the stock, reflecting heightened concerns over the company's profit margins and earnings trajectory despite reiterated full-year revenue guidance.